Kyoto, March 2 (Jiji Press)—An international clinical trial has confirmed that an antibody developed by Japan’s Chūgai Pharmaceutical Co. substantially eases itching caused by atopic dermatitis, a research team said Thursday.
An application for approval of a new drug based on the antibody, nemolizumab, will be submitted to the Japanese health ministry as early as 2019, after the team completes a larger-scale trial.
An article on the findings by the Japan-US-Europe team, including researchers from Kyoto University, will be published on the New England Journal of Medicine on Friday.
According to Kyoto University dermatology professor Kabashima Kenji, who participated in the research, past scientific reports show that itching from atopic dermatitis is associated with the interleukin-31 (IL-31) protein.
Chugai’s nemolizumab inhibits biological activity of IL-31 by preventing it from binding to its receptor.
[Copyright The Jiji Press, Ltd.]